Recently Expired Drugs
1. Drug name - AMITIZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(25 days ago) | |
| US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(25 days ago) | |
| US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(5 days ago) | |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 31 January, 2006
Treatment: Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient; Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient; Method for treating opioid-induced constipation
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 8MCG | CAPSULE;ORAL | Prescription |
| 24MCG | CAPSULE;ORAL | Prescription |
2. Drug name - AMLODIPINE BESYLATE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6828339 | SYNTHON PHARMS | Amlodipine salt forms and processes for preparing them |
Nov, 2022
(19 days ago) | |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 27 September, 2007
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2.5MG BASE | TABLET, ORALLY DISINTEGRATING;ORAL | Discontinued |
| EQ 5MG BASE | TABLET, ORALLY DISINTEGRATING;ORAL | Discontinued |
| EQ 10MG BASE | TABLET, ORALLY DISINTEGRATING;ORAL | Discontinued |
3. Drug name - BANZEL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(25 days ago) | |
Drugs and Companies using RUFINAMIDE ingredient
Market Authorisation Date: 03 March, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 40MG/ML | SUSPENSION;ORAL | Prescription |
4. Drug name - HETLIOZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(23 hours ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 31 January, 2014
Treatment: NA
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG | CAPSULE;ORAL | Prescription |
5. Drug name - HETLIOZ LQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(23 hours ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Dec 1, 2023 |
| Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: NA
Dosage: SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 4MG/ML | SUSPENSION;ORAL | Prescription |
6. Drug name - INBRIJA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7384649 | ACORDA | Particulate compositions for pulmonary delivery |
Nov, 2022
(19 days ago) | |
Drugs and Companies using LEVODOPA ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 42MG | POWDER;INHALATION | Prescription |
7. Drug name - NEURONTIN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7256216
(Pediatric) | VIATRIS | Liquid pharmaceutical compositions |
Nov, 2022
(11 days ago) | |
Drugs and Companies using GABAPENTIN ingredient
Market Authorisation Date: 02 March, 2000
Treatment: NA
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 250MG/5ML | SOLUTION;ORAL | Prescription |
8. Drug name - OCALIVA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7138390 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Nov, 2022
(23 days ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 27, 2023 |
Drugs and Companies using OBETICHOLIC ACID ingredient
Market Authorisation Date: 27 May, 2016
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
9. Drug name - PROMACTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(19 days ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
| Pediatric Exclusivity (PED) | Feb 26, 2022 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 20 November, 2008
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 12.5MG ACID | TABLET;ORAL | Prescription |
| EQ 25MG ACID | TABLET;ORAL | Prescription |
| EQ 50MG ACID | TABLET;ORAL | Prescription |
| EQ 75MG ACID | TABLET;ORAL | Prescription |
| EQ 100MG ACID | TABLET;ORAL | Discontinued |
10. Drug name - PROMACTA KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(19 days ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
| Pediatric Exclusivity (PED) | Feb 26, 2022 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 24 August, 2015
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 12.5MG ACID/PACKET | FOR SUSPENSION;ORAL | Prescription |
| EQ 25MG ACID/PACKET | FOR SUSPENSION;ORAL | Prescription |
11. Drug name - SELZENTRY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7368460 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2022
(14 days ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Oct 30, 2023 |
| Pediatric Exclusivity (PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 20MG/ML | SOLUTION;ORAL | Prescription |
12. Drug name - SUMAVEL DOSEPRO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8491524 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(18 days ago) | |
| US8241244 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(18 days ago) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 15 July, 2009
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | INJECTABLE;SUBCUTANEOUS | Discontinued |
| EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE;SUBCUTANEOUS | Discontinued |
13. Drug name - VEREGEN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10434059 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Nov, 2022
(21 days ago) | |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Treatment: Treatment of genital warts
Dosage: OINTMENT;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 15% | OINTMENT;TOPICAL | Prescription |
14. Drug name - VIIBRYD
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7834020
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(4 days ago) | |
|
US8193195
(Pediatric) | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(4 days ago) | |
|
US8236804
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(4 days ago) | |
|
US8673921
(Pediatric) | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(4 days ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 31, 2023 |
| Pediatric Exclusivity (PED) | Jul 31, 2023 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 January, 2011
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
15. Drug name - XERESE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7223387 | BAUSCH | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
Nov, 2022
(26 days ago) | |
Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); Combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older)
Dosage: CREAM;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 5%;1% | CREAM;TOPICAL | Prescription |
16. Drug name - XOFIGO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6635234 | BAYER HLTHCARE | Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning |
Nov, 2022
(22 days ago) | |
Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient
Market Authorisation Date: 15 May, 2013
Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 162mCi/6ML (27mCi/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.